11
Participants
Start Date
February 17, 2022
Primary Completion Date
March 20, 2023
Study Completion Date
March 20, 2023
spesolimab
solution for infusion
Nagoya City University Hospital, Aichi, Nagoya
Fukuoka University Hospital, Fukuoka, Fukuoka
Kagoshima University Hospital, Kagoshima, Kagoshima
Mie University Hospital, Mie, Tsu
Tohoku University Hospital, Miyagi, Sendai
Saitama Medical University Hospital, Saitama, Iruma-gun
Jichi Medical University Hospital, Tochigi, Shimotsuke
Teikyo University Hospital, Tokyo, Itabashi-ku
Tokyo Medical University Hospital, Tokyo, Shinjuku-ku
Lead Sponsor
Boehringer Ingelheim
INDUSTRY